Everything below concerns nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Hahn was shot in the back in October 1951 by a disgruntled inventor who wished to highlight the neglect of his ideas by mainstream scientists. Hahn was injured in a motor vehicle accident in 1952, and had a minor heart attack the following year. In 1962, he published a book, Vom Radiothor zur Uranspaltung (lit. 'From Radiothorium to Uranium Fission'). It was released in English in 1966 with the title Otto Hahn: A Scientific Autobiography, with an introduction by Glenn Seaborg. The success of this book may have prompted him to write another, fuller autobiography, Otto Hahn. Mein Leben, but before it could be published, he fractured one of the vertebrae in his neck while getting out of a car. He gradually became weaker and died in Göttingen on 28 July 1968. His wife Edith survived him by only a fortnight. He was buried in the Stadtfriedhof in Göttingen. The day after his death, the Max Planck Society published the following obituary notice:
FGFR1 oncogene partner 2 (FGFR1OP2) is a protein that in humans is encoded by the gene FGFR1OP2. It was identified in a study on myeloproliferative syndrome (EMS). The study aimed to identify the partner genes to the fibroblast growth factor receptor 1 (FGFR1) involved in the syndrome. Using the 5'-RACE PCR technique, FGFR1OP2 was identified as a novel gene with no known function.
=== Other events === A listening party for the album was held on the rooftop of the Louis Vuitton headquarters in Paris, France on June 23, 2025. Recordings of Lamar's verse on "Chains & Whips" subsequently circulated on social media. At approximately 11 p.m. Eastern Time on July 10, disc jockey and radio personality Ebro Darden hosted a live listening party of the album through Apple Music. An album-signing event was hosted on July 17, 2025, exclusively for customers who purchased a Let God Sort Em Out vinyl via Amoeba Music's Hollywood store.
Sources: en.wikipedia.org
has served on the Council of the British Records Association (1989–2005); the Council of the Royal Historical Society (1993–1996 and 1997–2000); and the Council of the List and Index Society (from 1997); has sat on the editorial boards of History Today, International History Review, Journal of Military History, Media History and the Journal of the Royal United Service Institution (now the RUSI Journal); awarded Samuel Eliot Morison Prize for lifetime achievement by the Society for Military History. Anthony Blond (20 March 1928 – 27 February 2008) publisher and author involved with several publishing companies over his career; of Sephardi ancestry; cousin of Harold Laski. Heston Blumenthal celebrity chef and author of over five books, was born in Shepherd's Bush, London, on 27 May 1966, to a Jewish father born in Southern Rhodesia and an English mother who converted to Judaism. His surname comes from a great-grandfather from Latvia and means 'flowered valley' (or 'bloom-dale'), in German.
Hematopoietic stem cells have also been discovered to be travelling in the blood stream and possess equal differentiating ability as other mesenchymal stem cells, again with a very non-invasive harvesting technique. There has been more recent interest in the use of extra embryonic mesenchymal stem cells. Research is underway to examine the differentiating capabilities of stem cells found in the umbilical cord, yolk sac and placenta of different animals. These stem cells are thought to have more differentiating ability than their adult counterparts, including the ability to more readily form tissues of endodermal and ectodermal origin.
== Background == Yu was born in Beijing, China. She received a master's degree in ancient Chinese literature and a doctoral degree in film & TV studies from Beijing Normal University. She holds strategist/researcher positions in a roster of mass media groups such as China Television Artists Association, China Visual Association's Tertiary Arts committee, China Visual Association's Research Group, CCTV's Research Office, China News Research Group, China-Guangdong Research Institute, China-Guangdong Institute Legal Programs Committee, News Corp (Australia), etc. Yu is apparently a fan of pop music idols such as Jay Chou and Nan Quan Mama, a Chinese classic enthusiast and a Kunqu Opera performer. She is also unofficially known as "the chieftain of the fun-seeking club of the School of Media and Arts at Beijing Normal University."
Opioids by mouth, including both weak opioids such as tramadol and stronger opioids, are also often prescribed. Their appropriateness is uncertain, and opioids are often recommended only when first-line therapies have failed or are contraindicated. This is due to their small benefit and relatively large risk of side effects. The use of tramadol likely does not improve pain or physical function and likely increases the incidence of adverse side effects. Oral steroids are not recommended in the treatment of osteoarthritis. Use of the antibiotic doxycycline orally for treating osteoarthritis is not associated with clinical improvements in function or joint pain and long term use is associated with a high risk of side effects. A 2018 meta-analysis found that oral collagen supplementation for the treatment of osteoarthritis reduces stiffness, but does not improve pain and functional limitation.
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.